INVO Fertility, Inc Stock Price, News & Analysis

INVO Fertility (NASDAQ: IVF) announced strategic enhancements to its INVOcell® technology program, including expanded clinical training support and improved pricing. INVOcell, the first FDA-cleared intravaginal culture system, offers a more natural fertility treatment alternative to traditional IVF with comparable pregnancy rates.

The company is strengthening its dual position as both a technology innovator and fertility clinic operator. Key features of INVOcell include using the woman's body as a natural incubator, demonstrated success rates comparable to conventional IVF, and increased accessibility for diverse family structures. The technology recently secured a new U.S. patent allowance and offers clinics improved operational efficiency.

INVO Fertility (Nasdaq: IVF) has announced the addition of Platelet-Rich Plasma (PRP) therapy to its fertility services at the Wisconsin Fertility Institute center. The treatment utilizes the body's own growth factors to stimulate uterine lining growth and ovarian rejuvenation, potentially improving implantation rates and ovarian response.

The therapy is specifically designed for women facing particular fertility challenges, including those with thin uterine lining, diminished ovarian reserve, and patients seeking alternatives before considering egg donation or surrogacy. Dr. Gretchen Collins, a double board certified OB/GYN and REI at Wisconsin Fertility Institute, notes that while PRP therapy remains experimental in fertility treatment, it has demonstrated success in other medical fields such as orthopedics and wound healing.

INVO Fertility (Nasdaq: IVF) has received a notice of allowance for a new patent extending protection of its modified INVOcell device through 2040. The patent (Application No. 16/949,960) covers a simplified design based on embryologist feedback, removing the separate microchamber in favor of a singular main chamber.

INVOcell is the world's first FDA-cleared intravaginal culture (IVC) system that enables fertilization and embryo development within a woman's body. The device, which delivers comparable pregnancy rates to traditional IVF, was first FDA-cleared in 2015 and received additional clearance in 2023 for an extended 5-day incubation period.

INVO Fertility (NASDAQ: IVF) has issued a reminder to shareholders to vote ahead of their Annual Meeting scheduled for June 25, 2025, at 12:00 p.m. ET. The virtual meeting is open to shareholders of record as of May 21, 2025. CEO Steve Shum emphasized the importance of shareholder support for the company's growth strategies, including plans to acquire profitable fertility clinics and expand INVOcell technology. Shum highlighted a robust pipeline of potential transactions for complementary revenue-generating services. Shareholders can vote through multiple channels: online at proxyvote.com, by mail, phone, or during the virtual meeting at virtualshareholdermeeting.com/INVO2025. The Board unanimously recommends voting "FOR" all proposals, which are detailed in the Proxy Statement filed with the SEC on June 4, 2025.

INVO Fertility (NASDAQ: IVF) has expanded telehealth capabilities at its Wisconsin Fertility Institute center to enhance access to fertility care. Dr. Gretchen Collins, medical director and fertility specialist, has obtained additional licenses in nine states including Illinois, Minnesota, Iowa, Montana, Colorado, Georgia, Alabama, Kansas, and Indiana. The telehealth platform enables virtual consultations, personalized fertility assessments, treatment planning, and ongoing support. While consultations and planning can be done remotely, critical procedures like egg retrievals and embryo transfers will continue to be performed at the clinic's physical location. This expansion aims to serve patients in rural and underserved areas, making specialized fertility care more accessible while maintaining high-quality in-person treatment standards.

INVO Fertility's Wisconsin Fertility Institute clinic has been named to Newsweek's America's Best Fertility Clinics for 2025. The prestigious recognition was based on four key criteria: CDC-published ART quality metrics, a nationwide survey of fertility specialists and medical professionals, accreditation data from major healthcare organizations (JCI, CAP, CLIA, AIUM), and patient satisfaction through Google reviews. The ranking, compiled in partnership with Statista, evaluates top facilities designated as fertility clinics and advanced reproductive technologies providers by the CDC.

INVO Fertility (NASDAQ: IVF), a healthcare services company focused on expanding access to advanced fertility treatments, has announced its participation in the upcoming Lytham Partners Spring 2025 Investor Conference on May 29, 2025. The company will engage in a virtual webcast fireside chat at 4:15 p.m. ET and conduct one-on-one meetings with investors throughout the event.

The webcast will be accessible through the conference homepage and will be available for replay after the event. Investors interested in one-on-one meetings with management can arrange them through Lytham Partners or by registering for the event directly on their website.

INVO Fertility (NASDAQ: IVF) reported its Q1 2025 financial results, marked by modest revenue growth and a strategic shift to focus exclusively on fertility operations. The company's revenue increased 4% to $1.64 million compared to Q1 2024. Consolidated clinic revenue from Atlanta and Madison locations grew 5% to $1.62 million. However, the company reported a significant net loss of $(17.4) million, largely due to a $14.6 million non-cash impairment charge related to NAYA Therapeutics assets. In April 2025, INVO announced plans to divest a majority stake in NAYA Therapeutics while maintaining a minority position for potential upside. The company is implementing growth initiatives at existing clinics and exploring expansion through acquisitions, aiming to achieve cash flow break-even and profitability.

INVO Fertility reported strong financial results for 2024, achieving a remarkable 116% annual revenue growth to $6.5 million. The company's Q4 2024 revenue reached $1.69 million, up 22% year-over-year.

Key highlights include a 125% increase in consolidated clinic revenue to $6.45 million and a 78% rise in total clinic revenue to $7.73 million. Despite these gains, the company recorded a net loss of $9.1 million, largely due to NAYA Therapeutics merger costs. However, Adjusted EBITDA improved significantly to $(2.2) million from $(4.9) million in 2023.

The company announced plans to divest its majority stake in NAYA Therapeutics to refocus on its core fertility operations. With three operating fertility centers in Wisconsin, Georgia, and Alabama, INVO aims to expand into additional markets, capitalizing on declining U.S. fertility rates and increasing demand for assisted reproductive technologies.